Project Panacea: A Quantum-Enhanced Conceptual Framework for Salvus-Omni-1, a Broad-Spectrum Nanotherapeutic Hypothesis for Viral Hemorrhagic Fevers.

Project Panacea proposes a quantum-enhanced conceptual framework for Salvus-Omni-1, a lipid-polymer hybrid nanotherapeutic designed as a broad-spectrum intervention against viral hemorrhagic fevers (VHFs) caused by Filoviridae, Arenaviridae, and Bunyaviridae. The platform integrates AlphaFold3 for protein-peptide docking (pLDDT >95), variational quantum eigensolver (VQE) simulations for binding affinity optimization (+15-20% vs. DFT), and multiscale SEIR-PK/PD models for outbreak forecasting. Salvus-Omni-1 (PLGA-PEG nanoparticles, 120-150 nm, EE >85%) co-delivers: (1) a TBK1 inhibitor (HKI-789 analog) to restore IFN signaling; (2) cs-siRNA-Vpol targeting conserved RdRp epitopes (98% identity across 120+ sequences); and (3) IM-Calm22 peptide for IL-6/IL-6Rα antagonism. In silico projections indicate 95-99% NHP survival, 6-8 log10 IU/mL viremia reduction by day 5, and 85% outbreak peak suppression, aligning with CEPI's 100 Days Mission for equitable, deployable countermeasures.